Insmed, Inc. $INSM Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Insmed by 89.5% in Q4, buying an additional 48,779 shares to hold 103,308 shares worth about $17.98 million.
• Insmed reported Q4 EPS of ($1.54), missing estimates by $0.47 while revenue was $263.84M; the stock opened down ~6% at $135.17 and trades well below its 52-week high of $212.75.
• Analysts remain broadly positive, with a consensus "Buy" rating and a consensus target price of $213.23, supported by multiple Buy/Strong Buy recommendations.

Universal Beteiligungs und Servicegesellschaft mbH boosted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 89.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 103,308 shares of the biopharmaceutical company's stock after purchasing an additional 48,779 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH's holdings in Insmed were worth $17,981,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. CIBC Private Wealth Group LLC raised its stake in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Insmed in the 4th quarter valued at $27,000. Stone House Investment Management LLC acquired a new position in Insmed in the 3rd quarter valued at $29,000. SBI Securities Co. Ltd. raised its stake in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 166 shares during the last quarter. Finally, GraniteShares Advisors LLC acquired a new position in Insmed in the 4th quarter valued at $30,000.

Analysts Set New Price Targets

Several research firms recently commented on INSM. Roth Mkm reissued a "buy" rating and issued a $212.00 price objective on shares of Insmed in a research note on Friday, April 17th. Truist Financial set a $205.00 price objective on Insmed in a research note on Monday, January 12th. Raymond James Financial began coverage on Insmed in a research note on Friday, April 10th. They issued an "outperform" rating and a $200.00 price objective for the company. Jefferies Financial Group began coverage on Insmed in a research note on Monday, March 16th. They issued a "buy" rating and a $228.00 price objective for the company. Finally, UBS Group reduced their price objective on Insmed from $223.00 to $215.00 and set a "buy" rating for the company in a research note on Tuesday, January 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $213.23.

Insmed Stock Down 6.0%

Shares of INSM opened at $135.17 on Friday. Insmed, Inc. has a 52-week low of $63.81 and a 52-week high of $212.75. The company has a market capitalization of $29.18 billion, a PE ratio of -21.09 and a beta of 1.10. The stock has a fifty day simple moving average of $149.27 and a two-hundred day simple moving average of $166.94. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. During the same period last year, the business earned ($1.32) earnings per share. The firm's revenue was up 152.6% compared to the same quarter last year. As a group, equities analysts forecast that Insmed, Inc. will post -2.51 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, insider Michael Alexander Smith sold 19,638 shares of the firm's stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24. Following the completion of the sale, the insider directly owned 51,871 shares of the company's stock, valued at $7,831,483.58. This trade represents a 27.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO William Lewis sold 10,699 shares of the firm's stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the completion of the sale, the chief executive officer directly owned 301,185 shares of the company's stock, valued at $43,361,604.45. This trade represents a 3.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 179,777 shares of company stock valued at $28,252,720 in the last three months. 2.10% of the stock is currently owned by insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.